(FRE) Fresenius SE & Co. KGaA - Ratings and Ratios

Fresenius SE & Co. KGaA (XETRA:FRE) is a global healthcare leader specializing in life-saving therapies and care for chronically ill patients. The company operates through four business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care is the largest segment, providing essential products and services for patients with chronic kidney failure, including dialysis machines, disposable products, and renal care services. Fresenius Kabi focuses on critical and chronic care, offering enteral and parenteral nutrition solutions, infusion technologies, and medical devices. Fresenius Helios operates a network of clinical and nursing care facilities, while Fresenius Vamed provides operational management and consulting services for healthcare facilities worldwide. Established in 1912 and headquartered in Bad Homburg vor der Höhe, Germany, Fresenius SE & Co. KGaA has grown into a diversified healthcare giant with a strong global presence.

Over the next three months, Fresenius SE & Co. KGaA is expected to maintain its stable financial trajectory. Based on , the stock is trading near its 20-day and 50-day moving averages (38.64 and 38.54, respectively), with a recent price of 39.01. The ATR of 1.18 indicates moderate volatility, while the stock remains above its 200-day SMA of 34.66, signaling long-term bullish momentum. From a perspective, the company’s forward P/E of 11.16 suggests potential undervaluation relative to its current P/E of 24.69. With a market cap of 22,247.86M EUR and a P/S ratio of 1.02, Fresenius is well-positioned for steady growth in the healthcare sector, supported by its diversified business model and strong market position.